Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial

Autor: Erin Furr Stimming, Daniel O Claassen, Elise Kayson, Jody Goldstein, Raja Mehanna, Hui Zhang, Grace S Liang, Dietrich Haubenberger, Jamie Adams, Christopher Beck, Cheryl Chen, Martha Nance, Claudia Testa, Patricia Huffman, Amy Chesire, Frederick Marshall, Praveen Dayalu, Angela Stovall, Deborah Hall, Jacob Hawkins, Letty Ginsburg, Henry Moore, Tiago Mestre, Tanya Thompson, Natalie Connors, H. Diana Rosas, Allison Daley, Sandra K. Kostyk, Casey Mitchell, Amy Hellman, Sheryl Houston, Danielle Buchanan, Katherine McDonell, Stewart A. Factor, Elaine Sperin, Andrea Hurt, Joanne Wojcieszek, Mike Adurogbangba, Lynn A. Raymond, Jody Corey-Bloom, Chase Snell, Courtney Blair, Victor Sung, Sophia Antonioli, Jacqueline Fung, Simon Laganiere, Luis Sierra, William M. Mallonee, Greg Suter, Danny Bega, Zsa Zsa Brown, Lawrence Elmer, Nancy Vollmar, Debra del Castillo, Yi-Han Lin, Kelly Andrzejewski, Patricia Weigel, Trevor Hawkins, Kendra Kirby, Cimmaron Retzik-Stahr, Lauren Seeberger, Rohit Dhall, Anja Rassmann, McKenzie Luxmore, Burton Scott, James Boyd, Katherine Chan, Nikolaus McFarland, Kyle Rizer, Patricia Conlon, Valerie Suski, Federico Rodriguez-Porcel, Sandra Wilson, Christine Farrell, David Hunter, David Houghton, Sarah Seoane, Clare Gibbons, Philippe Rizek, Robin Kuprewicz, Steven Lo, Miroslav Cuturic, Vicki Segro, Kate Greenly, Fredy Revilla, Enrique Urrea-Mendoza, Kevin J. Black, Thomas Davis, Natividad Stover, Andrew Duker, Jay Van Gerpen, Peter Hedera, William Ondo, Karen Anderson, Stephen Bradley, Ken Cheung, Samuel Frank

Publikováno v: The Lancet Neurology. 22:494-504

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9521bbc7c5886201c53a98dc988016d
https://doi.org/10.1016/s1474-4422(23)00127-8

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

Autor: Melanie Benge, Amie L. Hiller, Carolyn Gray, Michele Costigan, H. Diana Rosas, Stephanie Lowenhaupt, Rosalind S Chuang, Peter Hedera, Danny Bega, Matthew J. Barrett, Marianne Chase, Jon W. Yankey, Jessica Lamb, Elaine Sperin, Susan Perlman, Christina Gruenwald, Joseph F. Quinn, Joyce Ann Moran, Lauren Seeberger, Debra E Itzkowitz, Brenton A Wright, Kelly Lowen, Karen E. Anderson, Victor W. Sung, Angela Molloy, Frederick J. Marshall, Patricia Conlon, Hilda T Maibach, Jamie L Adams, Elaine Most, Stewart A. Factor, Karen Marder, Allison M. Daley, Shifang Lu, Carlos Singer, Michael J Brownstein, Neal G. Simon, Amy M Chesire, Valerie Suski, Codrin Lungu, Kellie Keith, Christopher S. Coffey, Guy J Schwartz, Zsazsa R Brown, Richard Dubinsky, Catherine Gladden, Paola Wall, Jeremy M. Shefner, Steven M. Hersch, Cara Jacob, Jeffrey D. Long, Dixie Ecklund, Padraig E. O'Suilleabhain, Andrew P. Duker, J. Singleton, Meghan Zorn, Carolyn Drazinic, Mark Quigg, Eve M Damiano, Sandra K. Kostyk, Brenda Thornell, Andrew McGarry, Merit Cudkowicz, Robin Conwit, Paul Deritis, Joel S. Perlmutter

Publikováno v: Journal of Clinical Medicine
Volume 9
Issue 11
Journal of Clinical Medicine, Vol 9, Iss 3682, p 3682 (2020)

SRX246 is a vasopressin (AVP) 1a receptor antagonist that crosses the blood-brain barrier. It reduced impulsive aggression, fear, depression and anxiety in animal models, blocked the actions of intranasal AVP on aggression/fear circuits in an experim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a6ab53df7b21fa094318e696048bfcc

Dance-based aerobic exercise for rheumatoid arthritis

Autor: Paul Caldron, Patricia Conlon, Susan G. Perlman, James Sinacore, Karen J. Connell, Andrea Clark, Marlena S. Robinson, Maureen R. Gecht

Publikováno v: Arthritis Care & Research. 3:29-35

Reported here are the results of the first effort to examine the effects of a dance-based aerobic exercise program for people with rheumatoid arthritis (RA). Forty-three subjects with RA completed a 16-week program that met twice weekly for 2 hours.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd9652a1e068607b39c00cdc96bb96c0
https://doi.org/10.1002/art.1790030106